Atlantic Eye Trials - LARVOL Sigma

Atlantic Eye	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Patel, Ravi

NCT01702805: Transfusion of Prematures Trial

Active, not recruiting

1824

Liberal Cell Transfusion, Restricted red cell transfusion

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia

01/20

08/25

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting

404

SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice

BriaCell Therapeutics Corporation

Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer

01/26

06/26

MIDAS, NCT06679855: Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Not yet recruiting

316

Milrinone infusion, Placebo infusion

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI)

Post-ligation Cardiac Syndrome

06/27

06/29

BiB, NCT04545866: The Budesonide in Babies () Trial

Active, not recruiting

1160

budesonide (Pulmicort nebulizing suspension)., Pulmicort nebulizing suspension., surfactant (poractant alfa;Curosurf), poractant alfa;Curosurf

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal

09/24

12/26

Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting

670

Europe, Canada, Japan, US, RoW

sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Carcinoma, Non-Small-Cell Lung

03/26

03/28

RadiCal, NCT04071223: Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Recruiting

134

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo

National Cancer Institute (NCI)

Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma

10/25

NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting

1/2

264

[203Pb]VMT01, [212Pb]VMT01, Nivolumab

Perspective Therapeutics

Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III

12/27

12/29

NeoRay, NCT03872778 / 2018-004727-37: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Active, not recruiting

1/2

Europe, US

[177Lu]-NeoB, Lutetium NeoB, [68Ga]-NeoB, Gallium NeoB, LCZ696, sacubitril/valsartan

Advanced Accelerator Applications, Advanced Accelerator Applications International SA

Neoplasms

11/25

12/26

Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting

N/A

Satera GSN Ablation, Sham Control

Axon Therapies, Inc.

Heart Failure With Preserved Ejection Fraction

04/22

03/23

ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting

N/A

44467

Guardant Health, Inc., Premier Research Group plc

Colorectal Cancer

03/24

12/25

CONCERTO, NCT05438732: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Recruiting

N/A

125

smaller incision, new generation implantable miniature telescope (SING-IMT)

VisionCare, Inc., ORA, Inc.

Age-Related Macular Degeneration, Geographic Atrophy

12/25

NeoPlaTT, NCT06676904: Neonatal Platelet Transfusion Threshold Trial

Not yet recruiting

N/A

2433

Higher Platelet Transfusion Threshold, Liberal Transfusion Threshold, Lower Platelet Transfusion Threshold, Restrictive Transfusion Threshold

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI)

Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis

01/31

04/31

NCT03927833: Cycled Phototherapy

Recruiting

N/A

1700

Phototherapy lights

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Hyper Bilirubinemia, Premature Infant

07/25

PREDICT, NCT03448926: The Registry:

Recruiting

N/A

3000

Treatment Recommendation Surveys, 7-gene biosignature

PreludeDx, University of South Florida

DCIS

12/25

12/35

NCT05685745: Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

Recruiting

N/A

5000

Europe, Canada, Japan, US

The University of Texas Health Science Center, Houston, Nationwide Children's Hospital, University of Iowa, University of Alabama at Birmingham, Jichi Medical University, Saitama Medical University

Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal

01/28

NCT00063063: Generic Database of Very Low Birth Weight Infants

Recruiting

N/A

80000

No Intervention

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature

03/30

Tsai, Alan C

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

Sherouse, Susan

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

Gonazlez, Yasniel Espinosa

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Patel, Ravi

NCT01702805: Transfusion of Prematures Trial

Active, not recruiting

1824

Liberal Cell Transfusion, Restricted red cell transfusion

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia

01/20

08/25

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting

404

SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice

BriaCell Therapeutics Corporation

Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer

01/26

06/26

MIDAS, NCT06679855: Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Not yet recruiting

316

Milrinone infusion, Placebo infusion

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI)

Post-ligation Cardiac Syndrome

06/27

06/29

BiB, NCT04545866: The Budesonide in Babies () Trial

Active, not recruiting

1160

budesonide (Pulmicort nebulizing suspension)., Pulmicort nebulizing suspension., surfactant (poractant alfa;Curosurf), poractant alfa;Curosurf

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal

09/24

12/26

Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting

670

Europe, Canada, Japan, US, RoW

sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Carcinoma, Non-Small-Cell Lung

03/26

03/28

Recruiting

134

National Cancer Institute (NCI)

10/25

NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting

1/2

264

[203Pb]VMT01, [212Pb]VMT01, Nivolumab

Perspective Therapeutics

Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III

12/27

12/29

NeoRay, NCT03872778 / 2018-004727-37: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Active, not recruiting

1/2

Europe, US

[177Lu]-NeoB, Lutetium NeoB, [68Ga]-NeoB, Gallium NeoB, LCZ696, sacubitril/valsartan

Advanced Accelerator Applications, Advanced Accelerator Applications International SA

Neoplasms

11/25

12/26

Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting

N/A

Satera GSN Ablation, Sham Control

Axon Therapies, Inc.

Heart Failure With Preserved Ejection Fraction

04/22

03/23

ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting

N/A

44467

Guardant Health, Inc., Premier Research Group plc

Colorectal Cancer

03/24

12/25

CONCERTO, NCT05438732: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Recruiting

N/A

125

smaller incision, new generation implantable miniature telescope (SING-IMT)

VisionCare, Inc., ORA, Inc.

Age-Related Macular Degeneration, Geographic Atrophy

12/25

NeoPlaTT, NCT06676904: Neonatal Platelet Transfusion Threshold Trial

Not yet recruiting

N/A

2433

Higher Platelet Transfusion Threshold, Liberal Transfusion Threshold, Lower Platelet Transfusion Threshold, Restrictive Transfusion Threshold

NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI)

Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis

01/31

04/31

NCT03927833: Cycled Phototherapy

Recruiting

N/A

1700

Phototherapy lights

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Hyper Bilirubinemia, Premature Infant

07/25

PREDICT, NCT03448926: The Registry:

Recruiting

N/A

3000

Treatment Recommendation Surveys, 7-gene biosignature

PreludeDx, University of South Florida

DCIS

12/25

12/35

NCT05685745: Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

Recruiting

N/A

5000

Europe, Canada, Japan, US

The University of Texas Health Science Center, Houston, Nationwide Children's Hospital, University of Iowa, University of Alabama at Birmingham, Jichi Medical University, Saitama Medical University

Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal

01/28

NCT00063063: Generic Database of Very Low Birth Weight Infants

Recruiting

N/A

80000

No Intervention

NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature

03/30

Tsai, Alan C

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

Sherouse, Susan

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24

Gonazlez, Yasniel Espinosa

NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting

RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control

ReGenTree, LLC

Neurotrophic Keratopathy

07/24

11/24



	Diseases Companies Products Productz Mechanisms of Action Sites